ATL 104

Drug Profile

ATL 104

Alternative Names: ATL104

Latest Information Update: 21 Feb 2012

Price : $50

At a glance

  • Originator Alizyme
  • Class
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Stomatitis

Most Recent Events

  • 01 Jan 2010 No development reported - Phase-II for Stomatitis in United Kingdom (PO)
  • 01 Jan 2010 No development reported - Phase-I/II for Stomatitis in Germany (PO)
  • 31 Jul 2009 Suspended - Phase-II for Stomatitis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top